Compile Data Set for Download or QSAR
maximum 50k data
Found 423 with Last Name = 'kawanami' and Initial = 't'
TargetSerine/threonine-protein kinase WNK1(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50258546(CHEMBL4087727)
Affinity DataKi:  32nMAssay Description:Allosteric inhibition of WNK1 (unknown origin) expressed in HEK293 cells co-expressing flag-OSR1 assessed as reduction in sorbitol-stimulated OSR1 ph...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM155343(US9006249, Example 49-2 | US9603819, Example 49-2)
Affinity DataIC50:  0.0300nMpH: 7.4 T: 2°CAssay Description:See A fluorescence lifetime-based assay for protease inhibitor profiling on human kallikrein 7 Doering K, Meder G, Hinnenberger M, Woelcke J, Mayr L ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM155343(US9006249, Example 49-2 | US9603819, Example 49-2)
Affinity DataIC50:  0.0300nMAssay Description:The activity of a compound according to the present invention can be assessed by the following in vitro & in vivo methods and/or by the following in ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM153121(US8993631, 29-2 | US9006249, Example 49-1)
Affinity DataIC50:  0.0400nMpH: 7.4 T: 2°CAssay Description:See A fluorescence lifetime-based assay for protease inhibitor profiling on human kallikrein 7 Doering K, Meder G, Hinnenberger M, Woelcke J, Mayr L ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM309469((2R,4S)-5-(3′-Chloro-biphenyl-4-yl)-4-[(3-hy...)
Affinity DataIC50:  0.0400nMAssay Description:The activity of a compound according to the present invention can be assessed by the following in vitro & in vivo methods and/or by the following in ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM138390(US8877786, Example 3-1)
Affinity DataIC50:  0.0900nMpH: 7.4 T: 2°CAssay Description:The in vitro inhibition of recombinant human neutral endopeptidase (NEP, EC 3.424.11) can be determined as follows:Recombinant human neutral endopept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM138396(US8877786, Example 3-13)
Affinity DataIC50:  0.200nMpH: 7.4 T: 2°CAssay Description:The in vitro inhibition of recombinant human neutral endopeptidase (NEP, EC 3.424.11) can be determined as follows:Recombinant human neutral endopept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM138395(US8877786, Example 3-12)
Affinity DataIC50:  0.200nMpH: 7.4 T: 2°CAssay Description:The in vitro inhibition of recombinant human neutral endopeptidase (NEP, EC 3.424.11) can be determined as follows:Recombinant human neutral endopept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM155344(US9006249, Example 49-3 | US9603819, Example 49-3)
Affinity DataIC50:  0.300nMpH: 7.4 T: 2°CAssay Description:See A fluorescence lifetime-based assay for protease inhibitor profiling on human kallikrein 7 Doering K, Meder G, Hinnenberger M, Woelcke J, Mayr L ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM155344(US9006249, Example 49-3 | US9603819, Example 49-3)
Affinity DataIC50:  0.300nMAssay Description:The activity of a compound according to the present invention can be assessed by the following in vitro & in vivo methods and/or by the following in ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM138391(US8877786, Example 3-2)
Affinity DataIC50:  0.300nMpH: 7.4 T: 2°CAssay Description:The in vitro inhibition of recombinant human neutral endopeptidase (NEP, EC 3.424.11) can be determined as follows:Recombinant human neutral endopept...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM153128(US8993631, 36)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of recombinant human NEP expressed in insect cells preincubated for 1 hr using Cys(PT14)-Arg-Arg-Leu-Trp-OH as substrate and measured afte...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM130359(US8822534, Example 5-39 | US8993631, 5-8)
Affinity DataIC50:  0.380nMAssay Description:Inhibition of recombinant human NEP expressed in insect cells preincubated for 1 hr using Cys(PT14)-Arg-Arg-Leu-Trp-OH as substrate and measured afte...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134505(US8846656, 21-D)
Affinity DataIC50:  0.5nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134531(US8846656, 23-I)
Affinity DataIC50:  0.5nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50509659(CHEMBL4443138)
Affinity DataIC50:  0.800nMAssay Description:Inhibition of recombinant human NEP expressed in insect cells preincubated for 1 hr using Cys(PT14)-Arg-Arg-Leu-Trp-OH as substrate and measured afte...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134582(US8846656, 56-F)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134580(US8846656, 56-C)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134523(US8846656, 21-AL)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134586(US8846656, 65-A)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134596(US8846656, 69-L)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134589(US8846656, 65-I)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134512(US8846656, 21-R)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134530(US8846656, 23-H)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134519(US8846656, 21-AH)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134518(US8846656, 21-AG)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134500(US8846656, 19-AF)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134511(US8846656, 21-Q)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM153108(US8993631, 16-5 | US9006249, Example 3-32 | US9603...)
Affinity DataIC50:  1nMpH: 7.4 T: 2°CAssay Description:See A fluorescence lifetime-based assay for protease inhibitor profiling on human kallikrein 7 Doering K, Meder G, Hinnenberger M, Woelcke J, Mayr L ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM153108(US8993631, 16-5 | US9006249, Example 3-32 | US9603...)
Affinity DataIC50:  1nMAssay Description:The activity of a compound according to the present invention can be assessed by the following in vitro & in vivo methods and/or by the following in ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134524(US8846656, 21-AM)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134577(US8846656, 55-M)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNicotinamide phosphoribosyltransferase(Homo sapiens (Human))
Novartis Institute For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50453428(CHEMBL4205098)
Affinity DataIC50: <1nMAssay Description:Inhibition of full length recombinant human NAMPT using N15-NAM as substrate preincubated for 15 mins followed by substrate addition and measured aft...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sidPDB
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Novartis Institutes For Biomedical Research

Curated by ChEMBL
LigandPNGBDBM50595702(CHEMBL5172637)
Affinity DataIC50:  1nMAssay Description:Inhibition of PRMT5 methyltransferase activity in human MTAP -/- Calu-6 cells assessed as reduction in SmB SDMA levels measured after 2 days by HTRF ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails PubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134574(US8846656, 55-I)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134520(US8846656, 21-AI)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134569(US8846656, 52-C)
Affinity DataIC50:  1nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM130365(US8822534, Example 11-1 | US8822534, Example 12-1 ...)
Affinity DataIC50:  1.5nMAssay Description:Inhibition of recombinant human NEP expressed in insect cells preincubated for 1 hr using Cys(PT14)-Arg-Arg-Leu-Trp-OH as substrate and measured afte...More data for this Ligand-Target Pair
TargetNeprilysin(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM50509652(CHEMBL4557208)
Affinity DataIC50:  1.60nMAssay Description:Inhibition of recombinant human NEP expressed in insect cells preincubated for 1 hr using Cys(PT14)-Arg-Arg-Leu-Trp-OH as substrate and measured afte...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134507(US8846656, 21-K)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134581(US8846656, 56-E)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134591(US8846656, 68-B)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134587(US8846656, 65-B)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134590(US8846656, 65-K)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134601(US8846656, 71-B)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134546(US8846656, 29)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134525(US8846656, 22-C)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134571(US8846656, 54-B)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134479(US8846656, 17-AM)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetC5a anaphylatoxin chemotactic receptor 1(Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM134529(US8846656, 23-G)
Affinity DataIC50:  2nMAssay Description:Compounds were tested for their ability to inhibit C5a-mediated calcium mobilization using a stable cell line over expressing the human C5aR & the Ga...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 423 total ) | Next | Last >>
Jump to: